Elutia Inc (NAS:ELUT)

$ 3.94 -0.21 (-5.06%) Market Cap: 136.18 Mil Enterprise Value: 133.57 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 56/100

Q3 2024 Elutia Inc Earnings Call Transcript
Nov 14, 2024

$3.83 (+2.13%)

Earnings
Q2 2024 Elutia Inc Earnings Call Transcript
Aug 07, 2024

$2.84 (-3.07%)

Earnings
Q4 2023 Elutia Inc Earnings Call Transcript
Mar 07, 2024

$3.59 (+1.70%)

Earnings
Q3 2023 Elutia Inc Earnings Call Transcript
Nov 13, 2023

$1.46 (-0.68%)

Earnings
Elutia Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
Sep 27, 2023
Q2 2023 Aziyo Biologics Inc Earnings Call Transcript
Aug 14, 2023

$1.34 (-2.90%)

Earnings
Q1 2023 Aziyo Biologics Inc Earnings Call Transcript
May 10, 2023

$2.47 (+4.22%)

Earnings
Q4 2022 Aziyo Biologics Inc Earnings Call Transcript
Mar 22, 2023

$1.19 (-2.46%)

Earnings
Aziyo Biologics Inc at Cowen Health Care Conference Transcript
Mar 06, 2023
Q3 2022 Aziyo Biologics Inc Earnings Call Transcript
Nov 14, 2022

$8.1 (+1.12%)

Earnings
Q2 2022 Aziyo Biologics Inc Earnings Call Transcript
Aug 11, 2022

$6.45

Earnings
Q1 2022 Aziyo Biologics Inc Earnings Call Transcript
May 09, 2022

$6.42 (-2.73%)

Earnings
Q4 2021 Aziyo Biologics Inc Earnings Call Transcript
Mar 03, 2022

$6 (-10.28%)

Earnings
Q3 2021 Aziyo Biologics Inc Earnings Call Transcript
Nov 09, 2021

$6.2 (-1.59%)

Earnings
Q2 2021 Aziyo Biologics Inc Earnings Call Transcript
Aug 09, 2021

$8.3 (+2.22%)

Earnings
Aziyo Biologics Inc Annual Shareholders Meeting Transcript
Jun 07, 2021
Q1 2021 Aziyo Biologics Inc Earnings Call Transcript
May 04, 2021

$9.51 (-1.55%)

Earnings
Aziyo Biologics Inc at Cowen Healthcare Conference (Virtual) Transcript
Mar 04, 2021
Q4 2020 Aziyo Biologics Inc Earnings Call Transcript
Mar 01, 2021

$15.51 (-2.58%)

Earnings
Q3 2020 Aziyo Biologics Inc Earnings Call Transcript
Nov 19, 2020

$12.28 (-5.47%)

Earnings

Q3 2022 Aziyo Biologics Inc Earnings Call Transcript

Nov 14, 2022 / 09:30PM GMT

Release Date Price: $8.1 (+1.12%)

Transcript 8-K10-Q

Operator

Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Aziyo Biologics Third Quarter 2022 Earnings Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference call over to Matt Steinberg, Fin Partners. Sir, the floor is yours.

Matt Steinberg;Finn Partners;Vice President

Thank you, operator, and thank you all for participating in today's call. Earlier today, Aziyo released financial results for the quarter ended September 30, 2022. A copy of the press release is available on the company's website. Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws, which are pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995.

Any statements contained in this call that do not relate to matters of historical facts or relate to expectations or predictions of future events,

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.